+1 more
TryptamineLSD, psilocybin, mescaline +4 moreLSD, psilocybin, mescaline, DMT, 1P-LSD, 1cP-LSD, 1V-LSD show less
ALD-52
1-acetyl-N,N-diethyllysergamide
ALD-52 (1-acetyl-LSD) is a semi-synthetic psychedelic of the lysergamide class. It is a prodrug of LSD — the body converts it to LSD almost immediately after ingestion.[1][2] That liberated LSD activates serotonin receptors in the brain, producing the visual and cognitive shifts of classical psychedelics.[3]
ALD-52 (1-acetyl-LSD) is a semi-synthetic psychedelic of the lysergamide class. It is a prodrug of LSD, rapidly converted to its parent compound by enzymatic hydrolysis after ingestion.[1][2] ALD-52 acts through LSD as a 5-HT₂A receptor agonist, producing its effects by disrupting the brain's default filtering of sensory and cognitive input.[3]
+1 more
TryptamineLSD, psilocybin, mescaline +4 moreLSD, psilocybin, mescaline, DMT, 1P-LSD, 1cP-LSD, 1V-LSD show less
Albert Hofmann synthesized ALD-52 at Sandoz in 1957 during a systematic exploration of LSD analogs.[4] It resurfaced in the 2010s as part of a wave of N1-acylated LSD analogs sold as legal alternatives on the research chemical market.[5] It remains unscheduled by name in most countries, though analog laws may apply where LSD is controlled.
Subjective effects include geometric visual patterns, time alteration, thought acceleration, emotional intensification, and ego dissolution. The experience is indistinguishable from LSD — a long, stimulating, sharply-edged alteration of perception and cognition. Thought loops, anxious fixation, and difficulty sleeping through its extended tail are common unwanted effects.
ALD-52 produces no physical dependence, and LSD — its active form — has no established lethal dose in humans.[3][6] The main risks are psychological: panic, distressing hallucinations, and rarely persistent visual disturbances;[7] MAOIs and tramadol can cause dangerous overheating and seizures when combined. No controlled human study of ALD-52 exists — all human-applicable data derives from the extensive LSD literature.
History[edit]
Discovery
Albert Hofmann and Franz Troxler synthesized ALD-52 at Sandoz in 1957 while systematically modifying LSD's structure.[4][8] It produced effects closely mirroring LSD but never entered formal development.
Clinical and Cultural Significance
ALD-52 is historically tied to the "Orange Sunshine" LSD case. Tim Scully and Nick Sand, arrested in 1973, claimed they had manufactured ALD-52 rather than LSD to exploit a scheduling gap — but the defense failed when prosecutors showed ALD-52 requires LSD as a synthetic intermediate and converts to it readily.[9] Both men were convicted, and later publicly confirmed Orange Sunshine was LSD.[10]
Re-emergence
ALD-52 resurfaced on the research chemical market in the 2010s alongside 1P-LSD, 1B-LSD, and other N1-acylated LSD analogs sold as legal alternatives.[5] Research confirmed all share the same prodrug mechanism.[11][12][13]
The name "ALD-52" reflects Sandoz's internal laboratory numbering. The shorthand "1A-LSD" describes the structure directly: 1-acetyl-LSD, the simplest possible acyl modification of the parent compound. As the shortest-chain member of the series, ALD-52 is the prototype from which all later analogs were developed.
Chemistry[edit]
Structural Class
ALD-52 belongs to the lysergamide family — semi-synthetic compounds built on the rigid ergoline ring system.[5][4] It is structurally identical to LSD except for a single acetyl group attached to the indole nitrogen at position 1.[8] Its molecular formula is C₂₂H₂₇N₃O₂.
That acetyl group is quickly cleaved by the body, releasing LSD as the active compound — making ALD-52 a prodrug.[1]
Pharmacology[edit]
Mechanism of Action
ALD-52 is a prodrug for LSD.[1] In its original form, the acetyl group blocks serotonin receptor binding — the compound is essentially pharmacologically inert. Once the body strips that group away, liberated LSD activates serotonin receptors in the cortex, producing the full psychedelic experience.[3][14]
Pharmacokinetics
The acetyl group is cleaved by enzymes in blood and liver,[2] releasing LSD rapidly into circulation.[1] This conversion step may produce a slightly slower onset than direct LSD — though no controlled comparison exists. LSD then reaches peak blood levels at around 1.1 hours, with a half-life of about 2.7 hours.[15]
People who metabolize LSD slowly through a liver enzyme called CYP2D6 experience roughly 75% more drug exposure — a longer, more intense effect.[16] This genetic variation is not detectable without testing.
Neuroscience[edit]
Where It Acts
No neuroimaging studies of ALD-52 exist. Its neural effects are understood through LSD research. LSD quiets the brain regions responsible for the ongoing sense of a continuous self — correlating with ego dissolution.[17]
LSD also disrupts the brain's normal sensory filter, allowing far more raw sensory information into awareness.[17] Greater connectivity between brain networks that normally operate separately accounts for the experience of perceptual novelty and intensity.
Why It Matters
LSD has been identified as a psychoplastogen — a compound that promotes rapid remodeling of neural connections in the brain's frontal regions.[17] These structural changes are hypothesized to underlie the lasting therapeutic effects seen in psychedelic clinical trials.
It is unknown whether ALD-52 crosses the blood-brain barrier intact — converting to LSD inside the brain — or whether conversion happens entirely in peripheral blood. This could affect which brain regions receive LSD first and how quickly effects build.
Subjective Effects[edit]
The ALD-52 experience is indistinguishable from LSD — expected, since the body converts it into LSD before effects begin.[1] The experience is sharply visual and cognitively activating: perception sharpens and then reorganizes entirely. Its emotional tone is highly sensitive to internal state and environment — the same dose can feel expansive or destabilizing depending on context.[18]
Within the lysergamide class, ALD-52 is pharmacologically equivalent to LSD at matching doses. Compared to psilocybin, it runs longer, feels more stimulating, and carries a sharper visual and cognitive edge. The prodrug conversion step may produce a slightly more gradual onset than direct LSD, though this remains unconfirmed.
Synthesized by Albert Hofmann at Sandoz Laboratories in 1957 during systematic lysergamide exploration,[4] ALD-52 saw limited clinical evaluation before decades of obscurity. It resurfaced in the 2010s as part of a wave of N1-acylated LSD analogs marketed as legal alternatives.[5] It remains unscheduled by name in most jurisdictions, though analog provisions may apply wherever LSD is controlled.
Subjective effects include geometric visual patterns, time alteration, thought acceleration, emotional intensification, and ego dissolution. The experience is indistinguishable from LSD — a slow-building, all-encompassing alteration of perception and cognition with a characteristically sharp lysergamide clarity and buzzing somatic electricity. Thought loops, anxious fixation, and difficulty sleeping through the extended tail are common unsought effects.
ALD-52 produces no physical dependence, and its active metabolite LSD has no established lethal dose in humans.[3][6] Rapid tolerance after a single dose deters compulsive use;[7] the primary risk is psychological — acute distress reactions and, rarely, HPPD.[8] No controlled human study of ALD-52 has been published; all human-applicable data derives from the extensive LSD literature.
History[edit]
Discovery
Albert Hofmann and Franz Troxler synthesized ALD-52 at Sandoz Laboratories in 1957 as part of a systematic program exploring structural modifications of LSD.[4] The compound — an acetyl group appended to LSD's indole nitrogen — was one of the earliest N1-acylated lysergamide derivatives.[9] It saw limited clinical evaluation during the 1960s, producing effects closely mirroring LSD, but never entered formal development.
Clinical and Cultural Significance
ALD-52 is historically entangled with the "Orange Sunshine" LSD tablets produced by Tim Scully and Nick Sand through the Brotherhood of Eternal Love in 1969. When arrested in 1973, the pair claimed they had manufactured ALD-52 — not LSD — exploiting the compound's absence from controlled substance schedules. The defense failed: the prosecution demonstrated that ALD-52 requires LSD as a synthetic intermediate and converts readily to it, and both men were convicted.[10] Scully and Sand later confirmed publicly that Orange Sunshine was LSD and the ALD-52 defense was fabricated.[11]
Re-emergence
ALD-52 resurfaced on the research chemical market in the 2010s alongside a wave of N1-acylated LSD analogs — 1P-LSD, 1B-LSD, 1cP-LSD, and 1V-LSD — sold as legal alternatives in jurisdictions where LSD was controlled. This proliferation prompted the "Return of the Lysergamides" research series beginning in 2016,[5] which identified ALD-52 as the foundational member of the 1-acyl LSD class and confirmed the shared prodrug mechanism across the series.[12][13][14]
The name "ALD-52" follows Sandoz's internal laboratory numbering. The shorthand "1A-LSD" reflects the structure directly: 1-acetyl-LSD, the simplest possible N1-acyl modification of the parent compound. As the shortest-chain member of the series (acetyl = two carbons), ALD-52 occupies the prototype position from which all subsequent analogs were designed.
Chemistry[edit]
Structural Class
ALD-52 belongs to the ergoline lysergamide family — semi-synthetic derivatives sharing the tetracyclic ergoline ring system of an indole fused to a partially hydrogenated quinoline. It is structurally identical to LSD except for an acetyl group (–COCH₃) attached to the indole nitrogen at position 1.[5][4][9]
This N1-acyl substitution defines an entire homologous series of LSD prodrugs: ALD-52 (acetyl, C2), 1P-LSD (propionyl, C3), 1B-LSD (butanoyl, C4), 1cP-LSD (cyclopropanoyl), 1V-LSD (valeroyl, C5), and longer-chain variants.[4] ALD-52, as the shortest-chain member, was the first synthesized and remains the prototypical compound.
Molecular Properties
| Molecular formula | C₂₂H₂₇N₃O₂ |
| Molecular weight | 365.5 g/mol |
The molecule retains LSD's ergoline core with the N,N-diethylcarboxamide at C-9 and N-methyl at N-6. The distinguishing acetyl group at N-1 adds 42 Da relative to LSD (323.4 g/mol).
Stereochemistry
ALD-52 has two chirality centers at C-6a and C-9, both in the R configuration — (6aR,9R). This matches the pharmacologically active (+)-LSD enantiomer. The ergoline scaffold constrains the ring junction to a trans-fused geometry, and only this diastereomer is pharmacologically relevant.
Physical Properties
No published characterization of ALD-52 salt forms, melting points, or solubility exists in peer-reviewed literature. As a lysergamide, it is expected to be sensitive to light, heat, and acidic conditions. The N1-acetyl group introduces an additional hydrolysis-labile site — readily cleaved under physiological conditions, which is central to its prodrug function.[1]
Pharmacology[edit]
Mechanism of Action
ALD-52 is a prodrug for LSD.[1] The acetyl group at N1 substantially reduces direct receptor binding — affinity for serotonin receptors drops by one to two orders of magnitude compared to LSD.[1] In functional assays, ALD-52 shows weak efficacy or antagonist behavior at serotonin receptor subtypes, making it pharmacologically near-inert in its parent form.[1]
Despite this, ALD-52 produces full psychedelic effects in vivo. High levels of LSD appear in plasma following ALD-52 administration, confirming rapid and efficient removal of the acetyl group.[1] The liberated LSD is the sole active moiety.
LSD acts primarily as a partial agonist at 5-HT₂A receptors in the cortex — the receptor responsible for psychedelic effects.[3][15] It also engages 5-HT₁A, dopamine D2, and adrenergic receptors, though 5-HT₂A activation drives the characteristic experience.[3]
Pharmacokinetics
The pharmacokinetic profile involves two phases: conversion of ALD-52 to LSD, then distribution and elimination of LSD.
Enzymatic hydrolysis cleaves the acetyl group in plasma and liver tissue,[2] liberating LSD. In vivo studies confirm rapid systemic conversion.[1] This deacylation step may introduce a slightly more gradual onset compared to LSD, though no controlled comparison exists.
Once liberated, LSD reaches peak plasma concentration at approximately 1.1 hours, with an half-life of approximately 2.7 hours.[16] Pharmacokinetics are dose-proportional across the standard range.[17] Genetic variation in CYP2D6 significantly affects LSD clearance: individuals who metabolize slowly experience approximately 75% higher drug exposure, longer duration, and more intense effects.[18]
Neuroscience[edit]
Where It Acts
No neuroimaging studies of ALD-52 have been published. As a prodrug for LSD, its neural effects are understood through LSD research. LSD reduces the coherence of the default mode network — brain regions governing self-referential thought and mind-wandering — which correlates with the subjective experience of ego dissolution.[19]
It simultaneously disrupts thalamic sensory filtering, allowing unregulated information to flood cortical processing areas, and increases communication between brain networks that normally operate independently.[19] This global increase in inter-network connectivity may underlie the unity and interconnectedness, novel insight, and perceptual novelty that characterizes the psychedelic state.
Why It Matters
The REBUS (Relaxed Beliefs Under Psychedelics) model proposes that psychedelics reduce the constraining influence of learned expectations on perception, allowing raw sensory information greater influence over conscious experience. LSD also qualifies as a psychoplastogen — a compound that promotes rapid structural remodeling of neural connections in prefrontal circuits through signaling cascades including BDNF release and mTOR pathway activation.[19] These neuroplastic effects are hypothesized to underlie sustained therapeutic outcomes observed in psychedelic clinical trials.
It is unknown whether ALD-52 crosses the blood-brain barrier intact and undergoes local conversion to LSD within neural tissue, or whether conversion occurs entirely in peripheral blood. The answer could affect regional brain concentrations and onset dynamics.
Subjective Effects[edit]
ALD-52's experiential character is indistinguishable from LSD — expected given its exclusive mechanism as an LSD prodrug.[1] The experience is profoundly sensitive to set and setting: identical doses can produce expansive aesthetic wonder or paralyzing anxiety depending on psychological state and environment.[20] Effects scale qualitatively across the dose range — lower amounts produce perceptual sharpening and mood lift, while higher amounts bring full ego dissolution, time loss, and deep cognitive restructuring.
Within the lysergamide class, ALD-52 is pharmacologically equivalent to LSD at equimolar doses. Compared to psilocybin, the experience is longer, more stimulating, and less sedating, with a sharper visual and cognitive edge. The prodrug conversion step may produce a subtly more gradual onset compared to direct LSD, though this remains unconfirmed in controlled settings.
Effect Grid
At common doses (75–150 µg oral), the full psychedelic experience emerges. Visual effects become pronounced: geometric patterns overlay surfaces, colors saturate and shift, objects drift and morph, tracers follow moving stimuli, and depth perception distortion alters spatial relationships. Closed-eye visuals include complex symmetrical texture repetition and internal hallucinations. Time dilation is marked. Thought connectivity increases dramatically, producing novel associations, conceptual thinking, and creativity enhancement. Emotional responses intensify — music, nature, and interpersonal interactions can feel profoundly meaningful. Cognitive euphoria is common.
Physically, muscle tension, increased heart rate, sweating, and appetite suppression are typical. Nausea occurs in a minority of users, usually during the come-up. Pupil dilation is pronounced.
A ceiling effect for positive drug effects occurs near 100 µg. Duration extends to 8–10 hours. Full functional impairment is expected; sleep is impossible for the duration.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Music enhancement · Geometry · Visual breathing · Holotropic state · Depth perception distortion · Perspective distortion · Symmetrical texture repetition · Brightness alteration · Environmental patterning · Light sensitivity · Visual morphing · Touch enhancement · After-images · Auditory distortion · Auditory enhancement · Sound sensitivity · Visual diffraction · Visual haze / noise · Ganzfeld effect · Auditory misinterpretation · Peripheral misidentification · Peripheral vision distortion · Proprioceptive distortion · Spatial disorientation · Visual acuity enhancement · Synesthesia · Vestibular distortion · Visual melting · Visual processing acceleration · Dreaming enhancement · Visual magnification · Olfactory enhancement · Taste enhancement · Flashbacks · Object transformations · Internal hallucinations · External hallucinations · Object activation · Visual recursion · Auditory hallucinations · Environmental orbism / cubism · Perspective hallucinations · Visual flipping · Visual scenery slicing · Persisting hallucinations · Shadow people
Depth perception distortion · Perspective distortion · Symmetrical texture repetition · Brightness alteration · Environmental patterning · Light sensitivity · Visual morphing · Touch enhancement · After-images · Auditory distortion · Auditory enhancement · Sound sensitivity · Visual diffraction · Visual haze / noise · Ganzfeld effect · Auditory misinterpretation · Peripheral misidentification · Peripheral vision distortion · Proprioceptive distortion · Spatial disorientation · Visual acuity enhancement · Synesthesia · Vestibular distortion · Visual melting · Visual processing acceleration · Dreaming enhancement · Visual magnification · Olfactory enhancement · Taste enhancement · Flashbacks · Object transformations · Internal hallucinations · External hallucinations · Object activation · Visual recursion · Auditory hallucinations · Environmental orbism / cubism · Perspective hallucinations · Visual flipping · Visual scenery slicing · Persisting hallucinations · Shadow people
Spontaneous body sensations · Appetite suppression · Insomnia · Body high · Heart rate perception changes · Body schema distortion · Bodily lightness · Muscle tension · Dry mouth · Physical fatigue · Tingling / electric sensations · Nausea · Involuntary body movements · Dizziness · Laughter fits · Restlessness · Tactile euphoria · Vasoconstriction · Vibrations / buzzing · Yawning · Sexual arousal enhancement · Excessive sweating · Increased urination · Bodily pressures · Breathing alteration · Headache · Nystagmus (eye wobbles) · Temperature dysregulation · Bodily heaviness · Dehydration sensation · Pain suppression · Trembling · Salivation · Bruxism · Diarrhea · Vomiting · Motor control enhancement · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Body high · Heart rate perception changes · Body schema distortion · Bodily lightness · Muscle tension · Dry mouth · Physical fatigue · Tingling / electric sensations · Nausea · Involuntary body movements · Dizziness · Laughter fits · Restlessness · Tactile euphoria · Vibrations / buzzing · Yawning · Sexual arousal enhancement · Excessive sweating · Increased urination · Bodily pressures · Breathing alteration · Headache · Nystagmus (eye wobbles) · Temperature dysregulation · Bodily heaviness · Dehydration sensation · Pain suppression · Trembling · Salivation · Bruxism · Diarrhea · Vomiting · Motor control enhancement · Seizure threshold reduction · Bodily dissociation · Tactile hallucination
Conceptual thinking · Cognitive euphoria · Multiple thought streams · Aesthetic enhancement · Cognitive flexibility · Introspection enhancement · Openness enhancement · Thought connectivity · Memory suppression · Thought acceleration · Thought disorganization · Thought loops · Cognitive impairment · Increased nature relatedness · Creativity enhancement · Memory fragmentation · Synchronicity · Humor enhancement · Analysis enhancement · Analysis suppression · Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory replays · Focus enhancement · Information processing enhancement · Cognitive dysphoria · Language suppression · Motivation suppression · Language enhancement · Motivation enhancement · Delusions
Aesthetic enhancement · Cognitive flexibility · Introspection enhancement · Openness enhancement · Thought connectivity · Memory suppression · Thought acceleration · Thought disorganization · Thought loops · Cognitive impairment · Increased nature relatedness · Creativity enhancement · Memory fragmentation · Synchronicity · Humor enhancement · Analysis enhancement · Analysis suppression · Cognitive fatigue · Confusion · Focus suppression · Information processing suppression · Memory replays · Focus enhancement · Information processing enhancement · Cognitive dysphoria · Language suppression · Motivation suppression · Language enhancement · Motivation enhancement
Anxiety · Simultaneous emotions · Catharsis · Empathy enhancement · Anxiety suppression · Dysphoria · Irritability · Mania
Empathy enhancement · Anxiety suppression · Dysphoria · Irritability
Social connection · Ego inflation · Trust enhancement · Communication enhancement · Flow state · Sociability enhancement · Communication suppression · Compulsive behavior reduction · Identity alteration · Boundary dissolution · Cognitive disconnection · Ego dissolution · Telepathic feelings
Flow state · Sociability enhancement · Communication suppression · Compulsive behavior reduction · Identity alteration · Boundary dissolution · Cognitive disconnection · Ego dissolution · Telepathic feelings
Time cessation
Non-dual awareness · Transpersonal memory access · Death-rebirth sequence · Entity contact
Mindfulness enhancement · Recursive awareness
Timeline
First alerts emerge as subtle shifts in color saturation, mild mood elevation, and a faint bodily awareness. The deacylation step from ALD-52 to LSD may extend onset slightly beyond LSD itself.
Effects build steadily: visual brightening intensifies, geometric patterning begins on textured surfaces, thought acceleration becomes noticeable, and emotional sensitivity increases. Mild nausea and muscle tension may appear during this phase.
Maximum intensity of all effect domains. Visual hallucinations, time dilation, conceptual thinking, and emotional intensification reach their zenith. Ego dissolution is possible at strong doses.
Effects remain clearly present but begin a gradual descent from peak intensity. Visual and cognitive effects persist with diminishing novelty. Emotional processing and reflective thought often deepen during this phase.
Progressive return toward baseline. Visual effects fade to subtle color enhancement and mild pattern recognition. Thought patterns normalize but may retain some fluidity.
Residual mood elevation, enhanced emotional openness, and mild perceptual sensitivity may persist for 4–12 hours after subjective effects resolve. Sleep quality may be reduced on the night following the experience.
⚠ Do not drive or operate heavy machinery until after a full night of sleep following the experience.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute Toxicity
LSD — and by extension ALD-52 — is physiologically non-toxic at standard doses.[3][6] No lethal dose has been established in humans. A review of five deaths previously attributed to LSD found two involved extreme overdoses, two resulted from physical restraint by police rather than drug effects, and one likely involved a different compound.[6]
Cardiovascular Effects
ALD-52 produces mild increases in heart rate and blood pressure, with no dangerous rhythm changes.[19] These effects are not clinically significant in healthy individuals.
Psychological Risks
Acute psychological distress — anxiety, panic, confusion, paranoia, and distressing hallucinations — can occur at any dose and increases sharply at higher amounts.[20] Unprepared users and uncontrolled environments amplify this risk substantially. Anyone with personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder) or bipolar disorder with psychotic features should avoid psychedelics.[3]
Chronic visual disturbances — tracers, halos, geometry persisting months to years after use — are a rare but severe risk known as hallucinogen persisting perception disorder (HPPD).[7][21]
Tolerance & Dependence
LSD and the psychedelic class produce no physical dependence or withdrawal.[3] Tolerance builds rapidly — essentially after a single dose — through serotonin downregulation.[22][23] Full sensitivity typically returns within 14 days.
ALD-52 shares full cross-tolerance with LSD, psilocybin, DMT, and mescaline.[23]
Drug Interactions
Dangerous Combinations
Combining ALD-52 with MAOIs or tramadol raises serotonin to dangerous levels.[24][25] The result can be serotonin syndrome — involuntary muscle contractions, dangerously high body temperature, and severe agitation.[25] These combinations are dangerous.
Lithium combined with psychedelics has been associated with increased seizure risk.safety citation needed
Attenuating Combinations
Chronic use of SSRIs or SNRIs blunts ALD-52's effects through serotonin receptor downregulation.[26] Those on these medications may experience significantly reduced or absent effects.
Metabolic Interactions
ALD-52 is converted to LSD by liver enzymes;[2] LSD is then cleared by a liver enzyme called CYP2D6.[16] Individuals who metabolize slowly through CYP2D6 experience roughly 75% more drug exposure and intensified, prolonged effects.[16]
Cannabis
The combination has not been formally studied. User reports indicate intensified and potentially prolonged psychedelic effects with increased anxiety and paranoia risk.
Contraindications
8 known- Psychotic disorders — personal or family history of schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features[3]
- Serotonergic medications — MAOIs, tramadol, and other serotonin-elevating agents[25][24]
- Lithium — seizure risk based on case-report evidencesafety citation needed
- Severe heart conditions — ALD-52 produces stimulant-like cardiovascular effects[19]
- Pregnancy — no safety data; contraindicated by precautionary principlecitation needed
Harm Reduction[edit]
Forms & Identification
ALD-52 is most commonly sold as blotter paper, occasionally as powder. Visual inspection cannot confirm identity or dose — it could contain LSD, another lysergamide, or a dangerous substitute such as an NBOMe. Reagent testing narrows possibilities but cannot distinguish between lysergamides. Mail-in analytical testing provides the most reliable identification.
Guidelines
- Test every sample with reagent kits before use. Ehrlich reagent should turn purple for lysergamides; no reaction means the substance is not as expected.
- Start with a low dose for a first experience or a new batch. ALD-52's prodrug conversion may produce a slower onset than LSD — do not redose early assuming inactivity.
- Arrange a sober sitter — someone trusted who remains undosed and available throughout.
- Prepare the space in advance: comfortable seating, water, light snacks, music, and easy access to a change of environment.
- Eat lightly beforehand. Avoid caffeine and alcohol on the day of use.
- If anxiety arises, change the immediate environment — move rooms, change music, step outside. Physical movement and sensory change are the most reliable de-escalation tools.
Set & Setting
The psychedelic experience is shaped as much by context as by pharmacology. Internal state — mood, expectations, unresolved anxieties — sets the trajectory. The physical and social environment determines whether difficult moments escalate or resolve.
A calm, familiar environment with trusted company provides the strongest foundation. Avoid novel social situations, crowds, and settings that could become overwhelming during a multi-hour experience. The day after should be free of obligations.
Aftercare & integration. The days following a psychedelic experience bring heightened emotional openness and cognitive flexibility. Allow at least one full rest day before returning to normal obligations. Sleep may be disrupted the first night — this is expected and resolves without intervention.
Write down impressions, images, and insights within the first 24–48 hours while they remain vivid. Not every experience carries a clear message; the pressure to extract meaning can itself become a source of distress. If difficult emotions or unusual perceptual experiences persist beyond one week, consult a mental health professional experienced with psychedelic integration.
Persistent visual disturbances — tracers, halos, after-images — that do not resolve warrant professional evaluation for HPPD.
Recovery & Support
ALD-52 does not produce physical dependence, and compulsive use is rare due to rapid tolerance. Psychological patterns of repeated use — using psychedelics to avoid difficult emotions, or substituting peak experiences for sustained personal work — can develop without physical addiction.
If psychedelic use is becoming a pattern that interferes with daily life, relationships, or mental health, support is available through psychedelic-informed therapists, harm reduction organizations such as the Zendo Project and Fireside Project, and peer communities. SAMHSA's helpline (1-800-662-4357) provides free, confidential referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Most difficult psychedelic experiences are uncomfortable but not medically dangerous. The distinction matters:
Uncomfortable but manageable: anxiety, thought loops, nausea, temporary confusion, crying, fear. These typically resolve with reassurance, environmental change, and time.
Requires immediate help: self-harm behavior, complete dissociation from reality with inability to communicate, seizure, chest pain, loss of consciousness, or sustained high body temperature.
- 1. Call emergency services. Do not wait to see if symptoms resolve if any red-flag signs are present.
- 2. Stay with the person. Speak calmly, use their name, orient them to where they are and that they have taken a substance.
- 3. Do not physically restrain unless there is immediate danger of self-harm or harm to others.
- 4. Move them to a quiet space with minimal stimulation if possible.
- 5. Place in the recovery position if they are unconscious or vomiting.
What to tell the dispatcher: the substance taken (ALD-52 or LSD structural analog), approximate amount, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
ALD-52 is not specifically named in most controlled substance schedules, but where LSD is controlled, structural analog provisions may treat it as equivalent.[27] Legal status changes rapidly; the information below reflects status as of April 2026.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class A controlled substance | Added to the Misuse of Drugs Act following advisory council recommendation, effective January 2015.[27] |
| Switzerland | Controlled substance | Listed in the Swiss controlled substance ordinance, effective March 2018.[27] |
| United States | Not specifically scheduled | Subject to the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption — prosecutable as a Schedule I substance under LSD analog theory.[27] |
| Canada | Unclear | Not specifically listed in the Controlled Drugs and Substances Act. May fall under general provisions for LSD analogs.[27] |
| Australia | Unclear | LSD is Schedule 9 under the Poisons Standard. ALD-52 status under analog provisions unconfirmed.[27] |
| Germany | Unclear | Not specifically named. Germany's NpSG (New Psychoactive Substances Act) may cover structural analogs of LSD.[27] |
| Finland, Latvia, Romania | Controlled | Listed as controlled substances.[27] |
Legal status changes rapidly and varies by jurisdiction. This information is not legal advice. Verify current status in the relevant jurisdiction before making any decisions.
Analog and Prodrug Considerations
ALD-52's legal vulnerability stems from two factors: its structural similarity to LSD subjects it to analog laws in many jurisdictions, and its confirmed prodrug status makes it pharmacologically equivalent to LSD administration.[9] The 1976 case United States v. Sand and Scully — in which ALD-52 was effectively treated as equivalent to LSD — remains a relevant enforcement precedent.[9]
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 14 days
- Physical
- None
- Psychological
- Negligible
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- LSD · psilo · mesc
Toxicity
Acute Toxicity
LSD — and by extension ALD-52 — is physiologically non-toxic at standard doses.[3][6] No lethal dose has been established in humans; in animal models, the lethal dose is orders of magnitude above the psychoactive dose.
A review of five deaths previously attributed to LSD toxicity found that two involved massive overdoses far exceeding standard use, two resulted from cardiovascular collapse during physical restraint by police rather than direct drug effects, and one likely involved a substituted compound (25I-NBOMe) rather than LSD.[6] No organ damage — liver, kidney, heart, or brain — has been documented at standard doses.[3]
Cardiovascular Effects
LSD produces mild-to-moderate increases in heart rate and blood pressure consistent with stimulant-like activation, with no dangerous heart rhythm changes.[21] These effects are not clinically significant in healthy individuals.
Psychological Risks
Acute psychological distress — anxiety, panic, confusion, paranoia, and distressing hallucinations — can occur at any dose but increases substantially at higher doses. Ego dissolution and anxiety increase markedly at 200 µg versus 100 µg LSD in controlled settings.[17] Unprepared users and uncontrolled settings amplify risk.
Hallucinogen persisting perception disorder (HPPD) involves chronic visual disturbances — tracers, halos, geometry — persisting months to years after LSD exposure.[8][22] HPPD is rare but can be severely debilitating. Treatment approaches include lamotrigine and benzodiazepines, with variable efficacy.
Psychotic episodes: Psychedelics are contraindicated in individuals with personal or family history of psychotic disorders (schizophrenia, schizoaffective disorder) or bipolar disorder with psychotic features. No ALD-52-specific data exist; this risk is extrapolated from LSD class literature.[3]
Tolerance & Dependence
LSD and the psychedelic class produce no physical dependence or withdrawal.[3] Tolerance develops rapidly — essentially after a single dose — through downregulation of serotonin receptors in the cortex.[7][23] Full sensitivity typically returns within 14 days.
This rapid tolerance functions as a biological deterrent to daily use. ALD-52 shares full cross-tolerance with LSD and other serotonergic psychedelics (psilocybin, DMT, mescaline).[23]
Drug Interactions
Dangerous Combinations
Tramadol elevates serotonin levels by blocking reuptake.[24] Combined with ALD-52/LSD, this can cause serotonin syndrome — a life-threatening condition involving involuntary muscle contractions, dangerously high body temperature, and agitation.[24][25]
MAOIs combined with serotonergic substances can cause dangerous serotonin syndrome.[25] Potentiation of effects is expected and the combination should be considered dangerous.
Lithium combined with psychedelics has been associated with increased seizure risk.safety citation needed
Attenuating Combinations
SSRIs/SNRIs taken chronically blunt LSD's effects through serotonin receptor downregulation.[26] Individuals on these medications may experience significantly reduced or absent effects from ALD-52.
Metabolic Interactions
ALD-52 is converted to LSD by liver enzymes;[2] LSD is cleared primarily by CYP2D6.[18] Individuals who metabolize slowly through CYP2D6 experience approximately 75% higher drug exposure and intensified, prolonged effects.[18]
Cannabis
The combination has not been formally studied. User reports indicate intensified and potentially prolonged psychedelic effects with increased anxiety and paranoia risk.
Contraindications
8 knownPsychotic disorders: Personal or family history of schizophrenia, schizoaffective disorder, or bipolar disorder with psychotic features.[3]
Concurrent serotonergic medications: MAOIs, tramadol, and other serotonin-elevating agents.[24][25]
Lithium: Seizure risk based on case-report evidence.safety citation needed
Severe heart conditions: LSD produces stimulant-like cardiovascular effects[21] that may pose risk to individuals with unstable cardiovascular conditions.
Pregnancy: No safety data exist. Use during pregnancy is contraindicated by precautionary principle.citation needed
Harm Reduction[edit]
Forms & Identification
ALD-52 is most commonly encountered as blotter paper, occasionally as powder. As with all blotter-distributed substances, the declared identity and dose cannot be verified visually — what is sold as ALD-52 could contain LSD, another lysergamide structural analog, or a more dangerous substituted compound such as an NBOMe. Reagent testing narrows the possibilities but cannot distinguish between lysergamides; quantitative testing through mail-in analytical services provides the most reliable identification.
Guidelines
- Test every sample with reagent kits before use. Ehrlich reagent should produce a purple reaction for lysergamides; absence of reaction indicates the substance is not what was expected.
- Start with a low dose if this is a first experience or a new batch. ALD-52's prodrug conversion may produce a slightly slower onset than LSD — do not redose early assuming the substance is inactive.
- Arrange a sober sitter — someone trusted who remains undosed and available throughout the experience.
- Prepare the space in advance: comfortable seating, water, light snacks, music, a notebook, and a change of environment accessible nearby.
- Eat lightly beforehand. Avoid caffeine and alcohol on the day of use.
- If anxiety arises, change the immediate environment — move rooms, change music, step outside. Physical movement and change of sensory input are the most reliable de-escalation tools.
Set & Setting
The psychedelic experience is shaped as much by context as by pharmacology. Internal state — mood, expectations, unresolved anxieties — sets the trajectory; the physical and social environment determines whether difficult moments escalate or resolve.
A calm, familiar environment with trusted company provides the strongest foundation. Outdoor settings with easy access to a private indoor space offer flexibility. Avoid novel social situations, crowds, or environments that could become overwhelming during a multi-hour experience. The day after should be free of obligations.
Aftercare & integration. The days following a psychedelic experience are a period of heightened emotional openness and cognitive flexibility. Allow at least one full rest day before returning to normal obligations. Sleep may be disrupted the first night — this is expected and resolves without intervention.
Write down impressions, images, and insights within the first 24–48 hours while they remain vivid. Not every experience carries a clear message, and the pressure to extract meaning can itself become a source of distress. If difficult emotions or unusual perceptual experiences persist beyond one week, consult a mental health professional experienced with psychedelic integration. Persistent visual disturbances (tracers, halos, after-images) that do not resolve warrant professional evaluation for HPPD.
Recovery & Support
ALD-52 does not produce physical dependence, and compulsive use is rare due to rapid tolerance. Psychological patterns of repeated use — using psychedelics to avoid processing difficult emotions, or relying on peak experiences as a substitute for sustained personal work — can develop without physical addiction.
If psychedelic use is becoming a pattern that interferes with daily life, relationships, or mental health, support is available through psychedelic-informed therapists, harm reduction organizations such as the Zendo Project and Fireside Project, and peer support communities. SAMHSA's helpline (1-800-662-4357) provides free, confidential referrals.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Most difficult psychedelic experiences are uncomfortable but not medically dangerous. The distinction matters:
Uncomfortable but manageable: anxiety, thought loops, nausea, temporary confusion, crying, fear. These typically respond to reassurance, environmental change, and time.
Requires immediate help: self-harm behavior, complete dissociation from reality with inability to communicate, seizure, chest pain, loss of consciousness, or sustained high body temperature.
- 1. Call emergency services. Do not wait to see if symptoms resolve if any red-flag signs are present.
- 2. Stay with the person. Speak calmly, use their name, orient them to where they are and that they have taken a substance.
- 3. Do not physically restrain unless there is immediate danger of self-harm or harm to others.
- 4. Move them to a quiet space with minimal stimulation if possible.
- 5. Place in the recovery position if they are unconscious or vomiting.
What to tell the dispatcher: the substance taken (ALD-52 or LSD analog), approximate amount, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
ALD-52 occupies a complex legal position internationally. It is not specifically named in most controlled substance schedules, so its legality often depends on structural analog provisions and prosecutorial interpretation. Where LSD is scheduled, ALD-52 may be treated as a controlled analog if sold or intended for human consumption. Legal status changes rapidly for new psychoactive substances; the information below reflects status as of April 2026.[27]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class A controlled substance | Added to the Misuse of Drugs Act following advisory council recommendation, effective January 2015.[27] |
| Switzerland | Controlled substance | Listed in the Swiss controlled substance ordinance, effective March 2018.[27] |
| United States | Not specifically scheduled | Subject to the Federal Analogue Act (21 U.S.C. § 813) if intended for human consumption — prosecutable as a Schedule I substance under LSD analog theory.[27] |
| Canada | Unclear | Not specifically listed in the Controlled Drugs and Substances Act. May fall under general provisions for LSD analogs.[27] |
| Australia | Unclear | LSD is Schedule 9 under the Poisons Standard. ALD-52 status under analog provisions unconfirmed.[27] |
| Germany | Unclear | Not specifically named. Germany's NpSG (New Psychoactive Substances Act) may cover structural analogs of LSD.[27] |
| Finland, Latvia, Romania | Controlled | Listed as controlled substances.[27] |
Analog and Prodrug Considerations
ALD-52's legal vulnerability stems from two factors: structural similarity to LSD subjects it to analog legislation in many jurisdictions, and its confirmed prodrug status makes it metabolically equivalent to LSD administration — strengthening the pharmacological basis for analog prosecution. The precedent set by United States v. Sand and Scully (1976)[10] — in which ALD-52 was effectively treated as equivalent to LSD — remains relevant to analog enforcement.
Frequently asked questions
What is ALD-52?
ALD-52 is a semi-synthetic ergoline lysergamide and prodrug for LSD, first synthesized by Albert Hofmann at Sandoz in 1957. It is rapidly deacylated in vivo to LSD, producing indistinguishable psychedelic effects across a 7–11 hour oral duration.
How long does ALD-52 last?
Total duration by route of administration — Oral: 7 – 11 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for ALD-52?
Psychedex publishes a dosage table for ALD-52 on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with ALD-52?
The highest-severity documented interactions for ALD-52: MAOIs (Lethal), Buspirone (Dangerous), DXM (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is ALD-52 addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for ALD-52: tolerance builds rapid; full reset takes 14 days; cross-tolerance develops with LSD, psilocybin, mescaline, DMT, 1P-LSD, 1cP-LSD, 1V-LSD. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2] ^abcWagmann L, Richter LHJ, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures — Analytical and Bioanalytical Chemistry doi:10.1007/s00216-018-1558-9
- [3]
- [4] ^abcKavanagh PV, Westphal F, Pulver B, Elliott S, Stratford A (2024) Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD) — Drug Testing and Analysis doi:10.1002/dta.3691
- [5] ^abcBrandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, Wallach J, Halberstadt AL (2016) Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD) — Drug Testing and Analysis doi:10.1002/dta.1884
- [6] ^abcNichols DE, Grob CS (2018) Is LSD toxic? — Forensic Science International doi:10.1016/j.forsciint.2018.01.006
references
- [1]
- [2] ^abcWagmann L, Richter LHJ, Kehl T, Wack F, Bergstrand MP, Brandt SD, Stratford A, Maurer HH, Meyer MR (2019) In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures — Analytical and Bioanalytical Chemistry doi:10.1007/s00216-018-1558-9
- [3]
- [4] ^abcdKavanagh PV, Westphal F, Pulver B, Elliott S, Stratford A (2024) Analytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD) — Drug Testing and Analysis doi:10.1002/dta.3691
- [5] ^abcBrandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, Wallach J, Halberstadt AL (2016) Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD) — Drug Testing and Analysis doi:10.1002/dta.1884
- [6] ^abcNichols DE, Grob CS (2018) Is LSD toxic? — Forensic Science International doi:10.1016/j.forsciint.2018.01.006